Published in J Acquir Immune Defic Syndr on December 01, 2012
Limited HIV infection of central memory and stem cell memory CD4+ T cells is associated with lack of progression in viremic individuals. PLoS Pathog (2014) 1.01
HIV DNA Set Point is Rapidly Established in Acute HIV Infection and Dramatically Reduced by Early ART. EBioMedicine (2016) 0.99
Immunologic and Virologic Progression in HIV Controllers: The Role of Viral "Blips" and Immune Activation in the ANRS CO21 CODEX Study. PLoS One (2015) 0.91
Virological and immunological characteristics of HIV-infected individuals at the earliest stage of infection. J Virus Erad (2016) 0.88
Differential levels of soluble inflammatory markers by human immunodeficiency virus controller status and demographics. Open Forum Infect Dis (2015) 0.86
Long-Term Non-Progression and Broad HIV-1-Specific Proliferative T-Cell Responses. Front Immunol (2013) 0.82
HIV Replication at Low Copy Number and its Correlation with the HIV Reservoir: A Clinical Perspective. Curr HIV Res (2015) 0.79
The natural history of HIV infection. Curr Opin HIV AIDS (2013) 0.78
Impaired human immunodeficiency virus type 1 replicative fitness in atypical viremic non-progressor individuals. AIDS Res Ther (2017) 0.77
Impaired human immunodeficiency virus type 1 replicative fitness in atypical viremic non-progressor individuals. AIDS Res Ther (2017) 0.75
A Subset of Extreme Human Immunodeficiency Virus (HIV) Controllers Is Characterized by a Small HIV Blood Reservoir and a Weak T-Cell Activation Level. Open Forum Infect Dis (2017) 0.75
Loss of long-term non-progressor and HIV controller status over time in the French Hospital Database on HIV - ANRS CO4. PLoS One (2017) 0.75
Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science (1996) 18.38
A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med (1997) 17.51
Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med (1999) 14.30
Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet (2009) 14.01
Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science (1998) 12.05
Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis (1999) 9.81
Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. JAMA (2006) 7.14
Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood (2004) 7.09
Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis. Am J Hum Genet (1998) 6.88
Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis (2008) 6.43
Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis (2008) 6.03
Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS (2003) 5.85
Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol (1997) 5.30
Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans. Nat Med (1999) 4.74
Population biology of HIV-1 infection: viral and CD4+ T cell demographics and dynamics in lymphatic tissues. Annu Rev Immunol (1999) 4.66
CD8 naive T cell counts decrease progressively in HIV-infected adults. J Clin Invest (1995) 3.97
CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load. J Immunol (2002) 3.85
HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin Infect Dis (2005) 3.77
Decay kinetics of human immunodeficiency virus-specific CD8+ T cells in peripheral blood after initiation of highly active antiretroviral therapy. J Virol (2001) 2.93
Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues. J Clin Invest (1999) 2.48
CD8+ T-lymphocyte activation in HIV-1 disease reflects an aspect of pathogenesis distinct from viral burden and immunodeficiency. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 2.45
Understanding the benign nature of SIV infection in natural hosts. J Clin Invest (2007) 2.43
Ultrasensitive monitoring of HIV-1 viral load by a low-cost real-time reverse transcription-PCR assay with internal control for the 5' long terminal repeat domain. Clin Chem (2006) 2.32
Elite control of HIV Infection: implications for vaccines and treatment. Top HIV Med (2007) 2.16
CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients. Clin Infect Dis (2006) 2.02
Altered representation of naive and memory CD8 T cell subsets in HIV-infected children. J Clin Invest (1995) 1.96
Preserved central memory and activated effector memory CD4+ T-cell subsets in human immunodeficiency virus controllers: an ANRS EP36 study. J Virol (2007) 1.74
Increased numbers of primed activated CD8+CD38+CD45RO+ T cells predict the decline of CD4+ T cells in HIV-1-infected patients. AIDS (1996) 1.64
Early levels of HIV-1 DNA in peripheral blood mononuclear cells are predictive of disease progression independently of HIV-1 RNA levels and CD4+ T cell counts. J Infect Dis (2005) 1.64
Detection of diverse variants of human immunodeficiency virus-1 groups M, N, and O and simian immunodeficiency viruses from chimpanzees by using generic pol and env primer pairs. J Infect Dis (2000) 1.52
Impact of 5 years of maximally successful highly active antiretroviral therapy on CD4 cell count and HIV-1 DNA level. AIDS (2004) 1.49
Detection of human immunodeficiency virus type 1 DNA in dried blood spots by a duplex real-time PCR assay. J Clin Microbiol (2005) 1.44
Low immune activation despite high levels of pathogenic human immunodeficiency virus type 1 results in long-term asymptomatic disease. J Virol (2007) 1.35
Quantification of integrated and total HIV-1 DNA after long-term highly active antiretroviral therapy in HIV-1-infected patients. AIDS (1999) 1.34
CD4+ T cell depletion in an untreated HIV type 1-infected human leukocyte antigen-B*5801-positive patient with an undetectable viral load. Clin Infect Dis (2008) 1.29
CD4 T cell count reconstitution in HIV controllers after highly active antiretroviral therapy. Clin Infect Dis (2010) 1.18
Parallel decline of CD8+/CD38++ T cells and viraemia in response to quadruple highly active antiretroviral therapy in primary HIV infection. AIDS (2002) 1.14
The role of CD8+ T-cell response in HIV infection. AIDS Rev (2004) 1.08
Genetic diversity of HIV type 1 in rural eastern Cameroon. J Acquir Immune Defic Syndr (2004) 1.00
Circular viral DNA and anomalous junction sequence in PBMC of HIV-infected individuals with no detectable plasma HIV RNA. Virology (2002) 0.99
HIV-1 DNA for the measurement of the HIV reservoir is predictive of disease progression in seroconverters whatever the mode of result expression is. J Clin Virol (2008) 0.96
Are long-term non-progressors very slow progressors? Insights from the Chelsea and Westminster HIV cohort, 1988-2010. PLoS One (2012) 0.94
Elite controllers display higher activation on central memory CD8 T cells than HIV patients successfully on HAART. AIDS Res Hum Retroviruses (2010) 0.91
Normalization of CD4+ cell numbers and reduced levels of memory CD8+ cells in blood and tonsillar tissue after highly active antiretroviral therapy in early HIV type-1 infection. AIDS Res Hum Retroviruses (2000) 0.81
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med (2008) 7.22
Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One (2010) 5.73
Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. BMJ (2011) 3.72
British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med (2008) 3.67
Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis (2010) 3.37
Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn's disease. Gut (2011) 3.11
Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology (2010) 2.81
Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count. AIDS (2007) 2.47
Missed opportunities for earlier HIV diagnosis within primary and secondary healthcare settings in the UK. AIDS (2008) 2.34
Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. AIDS (2014) 2.27
Characteristics of intestinal dendritic cells in inflammatory bowel diseases. Gastroenterology (2005) 2.25
British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med (2012) 2.24
HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era. Eur J Neurol (2010) 2.06
Antiretroviral treatment adherence among HIV patients in KwaZulu-Natal, South Africa. BMC Public Health (2010) 1.91
Cell surface receptors, virus entry and tropism of primate lentiviruses. J Gen Virol (2002) 1.72
Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120. J Virol (2008) 1.71
A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch Intern Med (2006) 1.67
Comparative evaluation of the automated Roche TaqMan real-time quantitative human immunodeficiency virus type 1 RNA PCR assay and the Roche AMPLICOR Version 1.5 conventional PCR assay. J Clin Microbiol (2007) 1.61
Late diagnosis in the HAART era: proposed common definitions and associations with mortality. AIDS (2010) 1.57
HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era. J Clin Oncol (2012) 1.55
Development of the antibody response in acute HIV-1 infection. AIDS (2004) 1.54
Brief communication: rituximab in HIV-associated multicentric Castleman disease. Ann Intern Med (2007) 1.54
Probiotic and prebiotic use in patients with inflammatory bowel disease: a case-control study. Inflamm Bowel Dis (2010) 1.48
Infection-triggered familial or recurrent cases of acute necrotizing encephalopathy caused by mutations in a component of the nuclear pore, RANBP2. Am J Hum Genet (2009) 1.47
Survey of select practice behaviors by primary care physicians on the use of opioids for chronic pain. Curr Med Res Opin (2006) 1.41
Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication. Antivir Ther (2008) 1.41
Symptoms are highly prevalent among HIV outpatients and associated with poor adherence and unprotected sexual intercourse. Sex Transm Infect (2010) 1.40
The prevalence of chromosomally integrated human herpesvirus 6 genomes in the blood of UK blood donors. J Med Virol (2007) 1.37
A whole genome screen for HIV restriction factors. Retrovirology (2011) 1.37
Classification of HHV-6A and HHV-6B as distinct viruses. Arch Virol (2013) 1.33
Detection of antibody-dependent complement-mediated inactivation of both autologous and heterologous virus in primary human immunodeficiency virus type 1 infection. J Virol (2005) 1.31
Suicidal ideation in UK HIV clinic attenders. AIDS (2008) 1.31
Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials. AIDS (2013) 1.29
When should HAART be initiated in pregnancy to achieve an undetectable HIV viral load by delivery? AIDS (2012) 1.29
A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individuals. J Acquir Immune Defic Syndr (2009) 1.28
Data linkage reduces loss to follow-up in an observational HIV cohort study. J Clin Epidemiol (2010) 1.26
Smokers with active Crohn's disease have a clinically relevant dysbiosis of the gastrointestinal microbiota. Inflamm Bowel Dis (2011) 1.22
Use of probiotics in the treatment of inflammatory bowel disease. J Clin Gastroenterol (2003) 1.21
Human herpesvirus 6 chromosomal integration in immunocompetent patients results in high levels of viral DNA in blood, sera, and hair follicles. J Clin Microbiol (2006) 1.20
Traditional complementary and alternative medicine and antiretroviral treatment adherence among HIV patients in Kwazulu-Natal, South Africa. Afr J Tradit Complement Altern Med (2009) 1.20
HIV testing in non-traditional settings--the HINTS study: a multi-centre observational study of feasibility and acceptability. PLoS One (2012) 1.18
Inhibition of NF-κB signaling in human dendritic cells by the enteropathogenic Escherichia coli effector protein NleE. J Immunol (2010) 1.17
Lv2, a novel postentry restriction, is mediated by both capsid and envelope. J Virol (2004) 1.16
Human herpesvirus 6 DNA levels in cerebrospinal fluid due to primary infection differ from those due to chromosomal viral integration and have implications for diagnosis of encephalitis. J Clin Microbiol (2007) 1.14
Evidence for the role of interferon-alfa production by dendritic cells in the Th1 response in celiac disease. Gastroenterology (2007) 1.14
Exploring staff attitudes to routine HIV testing in non-traditional settings: a qualitative study in four healthcare facilities. Sex Transm Infect (2012) 1.12
The promiscuous CC chemokine receptor D6 is a functional coreceptor for primary isolates of human immunodeficiency virus type 1 (HIV-1) and HIV-2 on astrocytes. J Virol (2005) 1.11
Treatment switches after viral rebound in HIV-infected adults starting antiretroviral therapy: multicentre cohort study. AIDS (2008) 1.11
Tuberculosis among people with HIV infection in the United Kingdom: opportunities for prevention? AIDS (2009) 1.09
Impact of early viral kinetics on T-cell reactivity during antiviral therapy in chronic hepatitis B. Antivir Ther (2007) 1.08
Comparative evaluation of the Seegene Seeplex RV15 and real-time PCR for respiratory virus detection. J Med Virol (2011) 1.08
Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression? AIDS (2008) 1.07
CD4 counts and the risk of systemic non-Hodgkin's lymphoma in individuals with HIV in the UK. Haematologica (2009) 1.07
Molecular investigations of an outbreak of parainfluenza virus type 3 and respiratory syncytial virus infections in a hematology unit. J Clin Microbiol (2007) 1.05
Excellent immunological recovery following CODOX-M/IVAC, an effective intensive chemotherapy for HIV-associated Burkitt's lymphoma. AIDS (2010) 1.05
Adherence to antiretroviral treatment in patients with HIV in the UK: a study of complexity. AIDS Care (2008) 1.05
Family studies in Crohn's disease: new horizons in understanding disease pathogenesis, risk and prevention. Gut (2011) 1.05
Controlling the HIV epidemic with antiretrovirals: IAPAC consensus statement on treatment as prevention and preexposure prophylaxis. J Int Assoc Provid AIDS Care (2013) 1.04
'My fear is to fall in love again...' how HIV-positive African women survive in London. Soc Sci Med (2005) 1.04
Human herpesvirus 6 integrates within telomeric regions as evidenced by five different chromosomal sites. J Med Virol (2008) 1.04
What factors are associated with patient self-reported health status among HIV outpatients? A multi-centre UK study of biomedical and psychosocial factors. AIDS Care (2012) 1.04
Human telomeres that carry an integrated copy of human herpesvirus 6 are often short and unstable, facilitating release of the viral genome from the chromosome. Nucleic Acids Res (2013) 1.04
Antiretrovirals and the use of traditional, complementary and alternative medicine by HIV patients in Kwazulu-Natal, South Africa: a longitudinal study. Afr J Tradit Complement Altern Med (2011) 1.03
Like a prayer: the role of spirituality and religion for people living with HIV in the UK. Sociol Health Illn (2008) 1.03
An envelope-determined, pH-independent endocytic route of viral entry determines the susceptibility of human immunodeficiency virus type 1 (HIV-1) and HIV-2 to Lv2 restriction. J Virol (2005) 1.01
Raltegravir treatment response in an HIV-2 infected patient: a case report. AIDS (2008) 1.01
Rituximab as retreatment for rituximab pretreated HIV-associated multicentric Castleman disease. Blood (2007) 1.01
96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study. Antivir Ther (2013) 1.01
CD4-dependent and CD4-independent HIV-2: consequences for neutralization. AIDS (2003) 1.01
Sexual behaviour of people living with HIV in London: implications for HIV transmission. AIDS (2007) 0.99
A MIQE-compliant real-time PCR assay for Aspergillus detection. PLoS One (2012) 0.99
Pregnant women with HIV infection can expect healthy survival: three-year follow-up. J Acquir Immune Defic Syndr (2006) 0.99
Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year study. J Hepatol (2005) 0.99
Successive switching of antiretroviral therapy is associated with high psychological and physical burden. Int J STD AIDS (2007) 0.98
British HIV Association guidelines for the management of hepatitis viruses in adults infected with HIV 2013. HIV Med (2013) 0.98
Comparative evaluation of the QIAGEN QIAsymphony® SP system and bioMérieux NucliSens easyMAG automated extraction platforms in a clinical virology laboratory. J Clin Virol (2011) 0.97
Disclosure of HIV status: the role of ethnicity among people living with HIV in London. J Acquir Immune Defic Syndr (2008) 0.97